Until present, there is a lack of specific pharmacological therapy designed to avoid induction of secondary brain injuries and delayed neuronal cell death [91] . There have been some significant advances in the field of therapeutic complement inhibitor development, in recent years [43, 74, [92] [93] [94] . While some of these inhibitors have been successfully tested in experimental head injury models (Table 1) [67, 68, 71, 80] , the "bench-tobedside" extrapolation to clinical applications in headinjured patients has yet to be accomplished [91] .